The company's presence highlights Dublin’s growing reputation as a destination for innovation, connectivity and business ...

Labcorp Holdings Inc (LH) reports a robust 9% revenue increase and a 19% rise in adjusted EPS, while navigating challenges in ...

Labcorp forecast lower annual revenue growth for its contract research unit on Tuesday, as a prolonged funding crunch continues to weigh on its early-stage drug development clients.

Q3 2025 Earnings Call Transcript October 28, 2025 Labcorp Holdings Inc. beats earnings expectations. Reported EPS is $4.18, ...

Healthcare diagnostics company Labcorp Holdings (NYSE:LH) in Q3 CY2025, with sales up 8.6% year on year to $3.56 billion. Its ...

Labcorp posts Q3 EPS of $4.18 and sales of $3.56 billion, exceeding estimates, while revising 2025 guidance amid strong ...

BLS revenue reached $799 million, up 8.3%, and adjusted operating income grew to $132 million. The quarter ended with an $8.6 billion backlog, and the BLS book-to-bill was 0.89 for the quarter and ...

Total revenues for the three months ended Sept. 30 were $3.56 billion, up from $3.28 billion in the third quarter of 2024 and matching the consensus Wall Street estimate.

Guidance Updates -- Full-year 2025 revenue growth guidance was narrowed to 7.4%-8%, with Adjusted EPS guidance was set at $16 ...

Labcorp delivered mixed third-quarter results, with higher sales and raised profit | Labcorp reported solid third-quarter ...

Labcorp boosted its 2025 adjusted per-share earnings target to a range between $16.15 and $16.50 a share from a prior projection of $16.05 to $16.50. The diagnostic testing company cut its revenue ...